Litcius/Paper detail

Potential use of RNA-dependent RNA polymerase (RdRp) inhibitors against SARS-CoV2 infection

Charles Allen, Sterling P. Arjona, Maryline Santerre, Bassel E. Sawaya

2020All Life18 citationsDOIOpen Access PDF

Abstract

Favipiravir and remdesivir, inhibitors of RNA-dependent RNA polymerase (RdRp) were recently suggested as a potential SARS-CoV2 inhibitors. Since favipiravir and remdesivir target a critical and a viral-specific process, discovering other small molecules that do the same to use as treatment could be beneficial in slowing the outbreak. Though there have been many suggested antivirals to treat SARS-CoV-2 infection, most treatments target host-associated pathways that may cause adverse effects, Small molecules inhibitors of RdRp may be the best remedy against the COVID-19 pandemic.

Topics & Concepts

FavipiravirRNA-dependent RNA polymeraseRNA polymeraseRNAVirologyBiologyPolymeraseCoronavirus disease 2019 (COVID-19)MedicineEnzymeGeneticsGeneBiochemistryDiseaseInfectious disease (medical specialty)PathologySARS-CoV-2 and COVID-19 ResearchViral gastroenteritis research and epidemiologyCOVID-19 Clinical Research Studies